CERS Butterfly Strategy
CERS (Cerus Corporation), in the Healthcare sector, (Medical - Devices industry), listed on NASDAQ.
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America.
CERS (Cerus Corporation) trades in the Healthcare sector, specifically Medical - Devices, with a market capitalization of approximately $585.1M, a beta of 1.77 versus the broader market, a 52-week range of 1.15-3.15, average daily share volume of 2.4M, a public-listing history dating back to 1997, approximately 614 full-time employees. These structural characteristics shape how CERS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.77 indicates CERS has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a butterfly on CERS?
A long call butterfly buys one lower-strike call, sells two ATM calls, and buys one higher-strike call, paying a small net debit for a defined-risk position that maxes out if the underlying pins the middle strike at expiration.
Current CERS snapshot
As of June 30, 2026, spot at $2.90, ATM IV 35.50%, IV rank 3.92%, expected move 10.18%. The butterfly on CERS below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this butterfly structure on CERS specifically: CERS IV at 35.50% is on the cheap side of its 1-year range, which favors premium-buying structures like a CERS butterfly, with a market-implied 1-standard-deviation move of approximately 10.18% (roughly $0.30 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated CERS expiries trade a higher absolute premium for lower per-day decay. Position sizing on CERS should anchor to the underlying notional of $2.90 per share and to the trader's directional view on CERS stock.
CERS butterfly setup
The CERS butterfly below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With CERS near $2.90, the first option leg uses a $2.76 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed CERS chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 CERS shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $2.76 | N/A |
| Sell 2 | Call | $2.90 | N/A |
| Buy 1 | Call | $3.05 | N/A |
CERS butterfly risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals the wing width minus net debit times 100 (reached when the underlying pins the middle strike); max loss equals the net debit times 100. Two breakevens at lower-wing plus debit and upper-wing minus debit.
CERS butterfly payoff curve
Modeled P&L at expiration across a range of underlying prices for the butterfly on CERS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use butterfly on CERS
Butterflies on CERS are pinning bets - traders use them when they expect CERS to settle near a specific level at expiration (often the prior close, a round number, or the max-pain strike) and want defined-risk exposure to that outcome.
CERS thesis for this butterfly
The market-implied 1-standard-deviation range for CERS extends from approximately $2.60 on the downside to $3.20 on the upside. A CERS long call butterfly is a pinning play: it pays maximum at the middle strike if CERS settles there at expiration, with the wing legs capping both the cost and the maximum loss to the net debit. Current CERS IV rank near 3.92% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on CERS at 35.50%. As a Healthcare name, CERS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to CERS-specific events.
CERS butterfly positions are structurally neutral / pin (limited-risk, limited-reward); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. CERS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move CERS alongside the broader basket even when CERS-specific fundamentals are unchanged. Always rebuild the position from current CERS chain quotes before placing a trade.
Frequently asked questions
- What is a butterfly on CERS?
- A butterfly on CERS is the butterfly strategy applied to CERS (stock). The strategy is structurally neutral / pin (limited-risk, limited-reward): A long call butterfly buys one lower-strike call, sells two ATM calls, and buys one higher-strike call, paying a small net debit for a defined-risk position that maxes out if the underlying pins the middle strike at expiration. With CERS stock trading near $2.90, the strikes shown on this page are snapped to the nearest listed CERS chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are CERS butterfly max profit and max loss calculated?
- Max profit equals the wing width minus net debit times 100 (reached when the underlying pins the middle strike); max loss equals the net debit times 100. Two breakevens at lower-wing plus debit and upper-wing minus debit. For the CERS butterfly priced from the end-of-day chain at a 30-day expiry (ATM IV 35.50%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a CERS butterfly?
- The breakeven for the CERS butterfly priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current CERS market-implied 1-standard-deviation expected move is approximately 10.18%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a butterfly on CERS?
- Butterflies on CERS are pinning bets - traders use them when they expect CERS to settle near a specific level at expiration (often the prior close, a round number, or the max-pain strike) and want defined-risk exposure to that outcome.
- How does current CERS implied volatility affect this butterfly?
- CERS ATM IV is at 35.50% with IV rank near 3.92%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.